Cemiplimab + Fianlimab [Fixed Dose Combination (FDC)] + CEMIPLIMAB + Ubletamig for endometrial neoplasms

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 19 Oct 2020: Trial registered, NCT04590326
  2. 8 Dec 2020: Trial started, NCT04590326

The trials

NCT04590326: A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab

State
Under way
Phase
Phase 1 and Phase 2
People
612 planned
Started
8 Dec 2020
Primary completion
8 Nov 2028
Arms
Module 1
Results
None posted
  1. 19 Oct 2020: Trial registered
  2. 8 Dec 2020: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.